Last reviewed · How we verify
177Lu-RAD204
Alpha-particle emitting radioligand targeting somatostatin receptors
Alpha-particle emitting radioligand targeting somatostatin receptors Used for Neuroendocrine tumors.
At a glance
| Generic name | 177Lu-RAD204 |
|---|---|
| Sponsor | Radiopharm Theranostics, Ltd |
| Drug class | Somatostatin receptor-targeting radioligand therapy |
| Target | Somatostatin receptors |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
177Lu-RAD204 is a radioligand therapy that selectively targets and destroys cancer cells expressing somatostatin receptors.
Approved indications
- Neuroendocrine tumors
Common side effects
- Nausea
- Vomiting
- Fatigue
Key clinical trials
- 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 177Lu-RAD204 CI brief — competitive landscape report
- 177Lu-RAD204 updates RSS · CI watch RSS
- Radiopharm Theranostics, Ltd portfolio CI